<DOC>
	<DOCNO>NCT02780024</DOCNO>
	<brief_summary>Glioblastoma Multiforme one common , unfortunately one aggressive brain tumor adults patient recur die disease median survival 16 month diagnosis . Current treatment patient newly diagnose Glioblastoma Multiforme ( GBM ) safe maximal surgical resection follow concomitant conventional Radiotherapy ( RT ) deliver 6 week + Temozolomide ( TMZ ) follow TMZ 6 12 cycle . Recent scientific research show Metformin , common drug use treat diabetes mellitus , may improve result treatment patient variety cancer , breast , colon , prostate cancer . Metformin attractive safe medication use group patient low toxicity . In center investigator use TMZ 2 week prior short course ( 4 week ) RT equivalent standard RT 6 week . Temozolomide use 2 week RT + TMZ , follow 6 12 cycle TMZ . Our result quiet encouraging median survival 20 month , acceptable toxicity .</brief_summary>
	<brief_title>Metformin , Neo-adjuvant Temozolomide Hypo- Accelerated Radiotherapy Followed Adjuvant TMZ Patients With GBM</brief_title>
	<detailed_description>Metformin , drug safe toxicity profile , attractive molecule test patient newly diagnose GBM phase I clinical trial . This base potential inhibit proliferation GBM CSCs mechanism action similar IR TMZ . Metformin , IR , TMZ stimulate AMPK lead subsequent inhibition cellular proliferation . Therefore , hypothesize addition Metformin concomitant IR TMZ may increase efficiency IR TMZ , currently consider standard care patient GBM . In addition , Metformin lower blood glucose level , subsequently reduce insulin Insulin-Growth-factors growth-promoting factor direct impact GBM cellular proliferation invasion . Metformin may improve outcome patient GBM add current treatment consist maximal safe surgical resection follow neo-adjuvant TMZ concomitant accelerate hypofractionated limited-margin XRT follow adjuvant TMZ . Our Neuro-Oncology group McGill University review result ongoing Phase II study patient GBM . A group 33 patient treat accord protocol , median follow-up 11 month , median survival 17.5 month compare favourably current result standard treatment beneficial 2-week shorten XRT treatment time . This phase II clinical trial ass feasibility overall toxicity add Metformin Neoadjuvant Temozolomide follow concomitant Temozolomide accelerate hypofractionated limited-margin radiotherapy follow adjuvant Temozolomide patient newly diagnose GBM . It expect propose study treatment improve median survival current value 20 month ( current MUHC Neo-adjuvant Phase 2 data ) 25 month . This mean improved outcome 25 % . Using one-tailed statistic , power 0.8 alpha 0.05 , sample size Phase II trial 50 patient .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Age : 18 year old Histological confirmation supratentorial GBM KPS &gt; 60 Neurological function 0 1 Adequate bone marrow define : Absolute neutrophil count ( ANC ) ≥ 1500 cells/mm3 . Platelets ≥ 100,000 cells/mm3 Hemoglobin ≥ 10 g/dl . Adequate renal function , define : Creatinine clearance &gt; 60 ml/min/1.73m2 ( use Cockcroft Gault equation eGFR ) within 14 day prior study registration Adequate hepatic function , define : Bilirubin 1.7 18.9 umol/L within 14 day prior study registration ALT ≤ 3 x normal range within 14 day prior study registration Neoadjuvant TMZ Metformin start within 4 week surgery Concomitant TMZ Metformin accelerate Hypofractionated EBRT start least 2 week adjuvant TMZ start date , later five week surgery . Surgical diagnosis/intervention may include : partial near total resection Patients must recover effect surgery , postoperative infection complication study registration . A diagnostic contrastenhanced MRI CT scan brain must perform preoperatively postoperatively . The postoperative scan must do within 28 day prior initiation neoadjuvant TMZ . Preoperative postoperative scan must type . Patients unable undergo MR imaging enrol provide pre postoperative contrastenhanced CT scan obtain sufficient quality . History/physical examination , include neurologic exam within 14 day prior study registration . Documentation steroid dos within 14 day prior study registration stable decrease steroid dose within 5 day prior registration . For female childbearing potential , negative serum pregnancy test within 72hours prior start TMZ Metformin . Women childbearing potential male participant must practice adequate contraception . Adequate tissue specimen MGMT status analysis . Able sign inform studyspecific consent Diabetic patient type I type II . No tissue provide MGMT promoter methylation status determination . Margin contrastenhanced residual mass closer 15 mm optic chiasm optic nerve . Prior invasive malignancy ( except nonmelanoma skin cancer ) unless disease free ≥ 3 year Recurrent multifocal GBM . Prior chemotherapy radiosensitizers cancer head neck region ; prior chemotherapy different cancer allowable . Severe , active comorbidity , define follow : Acute chronic renal failure . Unstable angina and/or congestive heart failure require hospitalization Transmural myocardial infarction within last 6 month Acute bacterial fungal infection require intravenous antibiotic time registration . Chronic Obstructive Pulmonary Disease exacerbation respiratory illness require hospitalization preclude study therapy time registration Acquired Immune Deficiency Syndrome ( AIDS ) base upon current CDC definition . Major medical illness psychiatric impairment investigator 's opinion prevent administration completion protocol therapy . Pregnancy woman childbearing potential men sexually active willing/able use medically acceptable form contraception ; exclusion necessary treatment involve study may significantly teratogenic . Pregnant lactate woman , due possible adverse effect develop foetus infant due study drug . Prior allergic reaction Temozolomide Metformin . Patients treat therapeutic clinical protocol within 30 day prior study entry participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Neo-Adjuvant Metformin</keyword>
	<keyword>Neo-Adjuvant Temozolomide</keyword>
	<keyword>Temozolomide accelerate hypofractionation</keyword>
	<keyword>Metformin accelerate hypofractionation</keyword>
	<keyword>Adjuvant Temozolomide</keyword>
	<keyword>Adjuvant Metformin</keyword>
</DOC>